You are currently on the new version of our website. Access the old version .
  • Tracked for
    Impact Factor
  • Indexed in
    Scopus
  • 28 days
    Time to First Decision

Organoids

Organoids is an international, peer-reviewed, open access journal on all aspects of organoids published quarterly online by MDPI.

All Articles (85)

Decellularized Extracellular Matrix for Organoids Development and 3D Bioprinting

  • Elena Gkantzou,
  • Alexandro Rodríguez-Rojas and
  • Aleksandra Chmielewska
  • + 4 authors

Organoids are three-dimensional multicellular structures that mimic key aspects of native tissues consisting ideal tools to study organ development and pathophysiology when incorporated in customized bioscaffolds. In vivo, the extracellular matrix (ECM) maintains tissue integrity and regulates cell adhesion, migration, differentiation, and survival through biochemical and mechanical signals. Tissue-derived decellularized extracellular matrix (dECM) can preserve organ-specific biochemical signals and cell-adhesive motifs, creating a bioactive environment that supports physiologically relevant organoid growth. 3D bioprinting technology marks a transformative phase in organoid research by enhancing the structural and functional complexity of organoid models and expanding their application in pharmacology and regenerative medicine. These systems enhance tissue modeling and drug testing while adhering to the principles of animal replacement, reduction, and refining (3Rs) in research. Remaining challenges include donor variability, limited mechanical stability, and the lack of standardized decellularization protocols that can be addressed by adopting quality and safety metrics. The combination of dECM-based biomaterials and 3D bioprinting holds great potential for the development of human-relevant, customizable, and ethically sound in vitro models for regenerative medicine and personalized therapies. In this review, we discuss the latest (2021–2025) developments in applying extracellular matrix bioprinting techniques to organoid technology, presenting examples for the most commonly referenced organoid types.

8 January 2026

The main steps and processes for the transformation of extracellular matrix into a bioink for 3D bioprinting applications. Three main phases (in blue) that contain several steps (in orange) are followed to reach from dECM bioink formulation to a 3D-printed biological model. Steps 1–4 are essential, while the specific steps during the 3D bioprinting phase (6–8) may vary depending on the characteristics of the final material and its intended application. Part of the figure was created with BioRender.

Organoids consisting of primary human cells, i.e., astrocytes, pericytes, and endothelial cells, form a functional blood–brain barrier (BBB) in vitro. The ability of FITC-dextran (70 kDa), calcium phosphate nanoparticles (100 nm), Escherichia coli bacteria (2 µm), and MS2 coliphages (27 nm, a model for viruses) to penetrate the BBB under normoxic and hypoxic conditions (2.5% oxygen) for up to 12 days was assessed by fluorescence microscopy and confocal laser scanning microscopy. All agents were fluorescently labeled to trace them inside the organoids. Under normoxia, FITC-dextran, calcium phosphate nanoparticles, E. coli bacteria and MS2 coliphages did not penetrate the BBB. However, oxygen deficiency (hypoxia) triggered the penetration of the BBB by FITC-dextran and E. coli cells. This was underscored by a strong hypoxic center inside the organoids that developed in the presence of E. coli bacteria.

2 January 2026

Schematic representation of the culture process of BBB organoids under normoxic and hypoxic conditions (image created with BioRender).

Over the past decade, organoids representing a wide range of tissues have been developed, with increasing efforts to enhance their complexity, maturity, and resemblance to the corresponding native organs [...]

8 December 2025

This schematic provides an overview of various human stem cell-derived organoid models and their potential applications as platforms for basic research, drug development, and preclinical testing, which may lead to new therapeutic options for patients. It also underscores the importance of establishing guidelines and fostering public discourse on the ethical, legal, and societal implications associated with emerging technologies in human organoid research. The image was created in BioRender (Wörsdörfer, P. (2025), https://BioRender.com/8310ef4, accessed on 3 December 2025).

Three-dimensional cell model systems such as tumour organoids allow for in vitro modelling of self-organized tissue with functional and histologic similarity to in vivo tissue. However, there is a need for standard protocols and techniques to confirm the presence of cancer within organoids derived from tumour tissue. The aim of this study was to assess the utility of a Nanostring gene expression-based machine learning classifier to determine the presence of cancer or normal organoids in cultures developed from both benign and cancerous stomach biopsies. A prospective cohort of normal and cancer stomach biopsies were collected from 2019 to 2022. Tissue specimens were processed for formalin-fixed paraffin-embedding (FFPE) and a subset of specimens were established in organoid cultures. Specimens were labelled as normal or cancer according to analysis of the FFPE tissue by two pathologists. The gene expression in FFPE and organoid tissue was measured using a 107 gene Nanostring codeset and normalized using the Removal of Unwanted Variation III algorithm. Our machine learning model was developed using five-fold nested cross-validation to classify normal or cancer gastric tissue from publicly available Asian Cancer Research Group (ACRG) gene expression data. The models were externally validated using the Cancer Genome Atlas (TCGA), as well as our own FFPE and organoid gene expression data. A total of 60 samples were collected, including 38 cancer FFPE specimens, 5 normal FFPE specimens, 12 cancer organoids, and 5 normal organoids. The optimal model design used a Least Absolute Shrinkage and Selection Operator model for feature selection and an ElasticNet model for classification, yielding area under the curve (AUC) values of 0.99 [95% CI: 0.99–1], 0.90 [95% CI: 0.87–0.93], and 0.79 [95% CI: 0.74–0.84] for ACRG (internal test), FFPE, and organoid (external test) data, respectively. The performance of our final model on external data achieved AUC values of 0.99 [95% CI: 0.98–1], 0.94 [95% CI: 0.86–1], and 0.85 [95% CI: 0.63–1] for TCGA, FFPE, and organoid specimens, respectively. Using a public database to create a machine learning model in combination with a Nanostring gene expression assay allows us to allocate organoids and their paired whole tissue samples. This platform yielded reasonable accuracy for FFPE and organoid specimens, with the former being more accurate. This study re-affirms that although organoids are a high-fidelity model, there are still limitations in validating the recapitulation of cancer in vitro.

5 December 2025

Histology and morphology of whole tissue and organoid specimens. Representative images of normal and cancer tissues for two enrolled patients. Patient identification and normal/cancer designation denoted by top labels. Specimen type is denoted by the left labels. Whole tissue and organoid formalin-fixed paraffin-embedded (FFPE) are stained with hematoxylin and eosin (top two rows). In vitro images of organoids taken through Matrigel during initial passage for patient 55 and passage 1 for patient 54 (last row). Images captured at 20× using AxioCam HRc camera. The scale bar represents 50 μm. Note that this figure contains novel images of organoids used in previous research (see Section 2).

News & Conferences

Issues

Open for Submission

Editor's Choice

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Organoids - ISSN 2674-1172